Jan Sahai, PharmD; Gary Garber, MD; Keith Gallicano, PhD; Linda Oliveras, BSc; D. William Cameron, MD
To investigate 1) the effects of the magnesium-aluminum antacids in didanosine tablets on dapsone absorption in healthy volunteers and 2) the effects of the antacid formulation of active didanosine tablets on dapsone pharmacokinetics in patients seropositive for human immunodeficiency virus (HIV).
Two separate, randomized, two-period, two-treatment, crossover studies with a 21-day washout period between treatments.
Clinical investigation unit of a university hospital.
Six healthy men and six HIV-positive men.
Serial dapsone plasma concentrations were measured when dapsone, 100 mg, was administered alone and with either the third of four doses of didanosine placebo tablets (group 1) or the 27th of 28 doses of active didanosine tablets (group 2). In each study, pharmacokinetic variables were determined using noncompartmental methods and compared by analysis of variance.
When dapsone was administered alone, pharmacokinetic variables did not significantly differ from those with dapsone given in either combination (P > 0.10 for all comparisons).
Didanosine, antacids, and other excipients in the currently used didanosine chewable tablets did not significantly affect plasma concentrations of dapsone.
Sahai J, Garber G, Gallicano K, et al. Effects of the Antacids in Didanosine Tablets on Dapsone Pharmacokinetics. Ann Intern Med. 1995;123:584–587. doi: 10.7326/0003-4819-123-8-199510150-00003
Download citation file:
Published: Ann Intern Med. 1995;123(8):584-587.
HIV, Hospital Medicine, Infectious Disease.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use